title: Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries.
abstract: OBJECTIVE
  The purpose of the present analysis was to analyze and compare the cost-effectiveness of solifenacin flexible dosing (5-10 mg) with tolterodine 4 mg sustained release (SR) or placebo (assumed to be comparable to no treatment) for patients with overactive bladder (OAB) symptoms.
  
  
  METHODS
  A decision-analytic model was constructed.
  
  
  METHODS
  Costs and effects were evaluated for the three treatment options in a one-year timeframe. Costs included were treatment costs, cost of pad use, and patients productivity loss based on data from the Nordic countries.
  
  
  METHODS
  Results from two randomized controlled trials were used as input data in the cost-effectiveness analysis.
  
  
  METHODS
  Quality adjusted life years and incremental cost-effectiveness ratio.
  
  
  RESULTS
  Solifenacin flexible dosing was more effective with respect to reducing OAB symptoms compared to both placebo and tolterodine 4 mg. Treatment with both solifenacin and tolterodine was more costly compared to placebo, but treatment with solifenacin was a less costly alternative compared to tolterodine 4 mg SR. Sensitivity analyses revealed that the conclusions were robust.
  
  
  CONCLUSIONS
  Solifenacin flexible dosing was a cost-effective treatment alternative compared to tolterodine 4 mg SR.
authors.affiliation: Department of Obstetrics & Gynecology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. ian.milsom@gu.se
authors.forename: Ian
authors.initials: I
authors.lastname: Milsom
authors.forename: Susanne
authors.initials: S
authors.lastname: Axelsen
authors.forename: Sigurd
authors.initials: S
authors.lastname: Kulseng-Hansen
authors.forename: Anders
authors.initials: A
authors.lastname: Mattiasson
authors.forename: Carl Gustaf
authors.initials: CG
authors.lastname: Nilsson
authors.forename: Jannie
authors.initials: J
authors.lastname: Wickstrøm
mesh_terms: D001559:Benzhydryl Compounds / Q000008:administration & dosage; D003362:Cost-Benefit Analysis; D003408:Cresols / Q000008:administration & dosage; D003661:Decision Support Techniques; D005260:Female; D005387:Finland; D006801:Humans; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000191:economics; D010665:Phenylpropanolamine / Q000008:administration & dosage; D011812:Quinuclidines / Q000008:administration & dosage* / Q000191:economics; D016032:Randomized Controlled Trials as Topic; D012537:Scandinavian and Nordic Countries; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage* / Q000191:economics; D000068737:Tolterodine Tartrate; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000191:economics*
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; D000069464:Solifenacin Succinate